

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q

(Mark One)

(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 1998

OR

() TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number 0-19034

REGENERON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

New York

13-3444607

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer Identification No.)

777 Old Saw Mill River Road
Tarrytown, New York

10591-6707

(Address of principal executive offices)

(Zip code)

(914) 347-7000

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.

Yes X No

Indicate the number of shares outstanding of each of the issuer's classes of
common stock as of October 30, 1998:

Class of Common Stock -----	Number of Shares -----
Class A Stock, \$0.001 par value	3,631,986
Common Stock, \$0.001 par value	27,383,018

REGENERON PHARMACEUTICALS, INC.
Table of Contents
September 30, 1998

Page Numbers

PART I FINANCIAL INFORMATION

Item 1 Financial Statements

Condensed balance sheets (unaudited) at September 30, 1998
and December 31, 1997

Condensed statements of operations (unaudited) for the three months and nine months ended September 30, 1998 and 1997	4
Condensed statement of stockholders' equity (unaudited) for the nine months ended September 30, 1998	5
Condensed statements of cash flows (unaudited) for the three months and nine months ended September 30, 1998 and 1997	6
Notes to condensed financial statements	7-11
Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations	12-21
PART II OTHER INFORMATION	
Item 6 Exhibits and Reports on Form 8-K	22
SIGNATURE PAGE	23
Exhibit 27 Financial data schedule	

PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS

REGENERON PHARMACEUTICALS, INC.
CONDENSED BALANCE SHEETS AT SEPTEMBER 30, 1998 AND DECEMBER 31, 1997 (Unaudited)
(In thousands, except share data)

ASSETS	September 30, 1998 -----	December 31, 1997 -----
Current assets		
Cash and cash equivalents	\$ 22,594	\$ 28,921
Marketable securities	59,993	63,602
Receivable due from The Procter & Gamble Company	2,536	2,403
Receivable due from Merck & Co., Inc.	2,072	1,707
Receivable due from Amgen-Regeneron Partners	727	356
Receivable due from Sumitomo Pharmaceuticals Co., Ltd.	66	2,115
Prepaid expenses and other current assets	1,229	536
	-----	-----
Total current assets	89,217	99,640
Marketable securities	37,791	35,518
Investment in Amgen-Regeneron Partners	2,631	364
Property, plant and equipment, at cost, net of accumulated depreciation and amortization	32,646	32,713
Other assets	154	145
	-----	-----
Total assets	\$ 162,439 =====	\$ 168,380 =====
LIABILITIES and STOCKHOLDERS' EQUITY		
Current liabilities		
Accounts payable and accrued expenses	\$ 4,395	\$ 4,663
Deferred revenue, current portion	3,429	4,182
Capital lease obligations, current portion	1,739	1,770
Note payable, current portion	65	73
	-----	-----
Total current liabilities	9,628	10,688
Deferred revenue	12,996	14,801
Capital lease obligations	1,064	2,077
Note payable	1,626	1,675
Other liabilities	272	242

Stockholders' equity		
Preferred stock, \$.01 par value; 30,000,000 shares authorized; issued and outstanding - none		
Class A Stock, convertible, \$.001 par value; 40,000,000 shares authorized;		
3,631,986 shares issued and outstanding in 1998		
4,117,540 shares issued and outstanding in 1997	4	4
Common Stock, \$.001 par value; 60,000,000 shares authorized;		
27,382,858 shares issued and outstanding in 1998		
26,804,941 shares issued and outstanding in 1997	27	27
Additional paid-in capital	308,547	308,109
Unearned compensation	(450)	(720)
Accumulated deficit	(171,692)	(168,608)
Accumulated other comprehensive income	417	85
	-----	-----
Total stockholders' equity	136,853	138,897
	-----	-----
Total liabilities and stockholders' equity	\$ 162,439	\$ 168,380
	=====	=====

The accompanying notes are an integral part of the financial statements.

3

REGENERON PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF OPERATIONS (Unaudited)
(In thousands, except per share data)

	Three months ended September 30,		Nine months ended September 30,	
	1998	1997	1998	1997
	-----	-----	-----	-----
Revenues				
Contract research and development	\$ 3,983	\$ 3,277	\$ 14,759	\$ 11,892
Research progress payments	4,500	2,500	9,500	2,500
Contract manufacturing	2,326	1,304	6,493	2,859
Investment income	1,757	1,792	5,259	4,452
	-----	-----	-----	-----
	12,566	8,873	36,011	21,703
	-----	-----	-----	-----
Expenses				
Research and development	9,891	6,803	27,095	20,760
Loss in Amgen-Regeneron Partners	678	655	1,551	2,834
General and administrative	1,323	1,428	4,400	4,580
Depreciation and amortization	681	970	2,330	3,336
Contract manufacturing	1,286	750	3,389	1,719
Interest	102	174	330	580
	-----	-----	-----	-----
	13,961	10,780	39,095	33,809
	-----	-----	-----	-----
Net loss	(\$ 1,395)	(\$ 1,907)	(\$ 3,084)	(\$12,106)
	=====	=====	=====	=====
Net loss per share, basic and diluted	(\$ 0.04)	(\$ 0.06)	(\$ 0.10)	(\$ 0.43)
	=====	=====	=====	=====

The accompanying notes are an integral part of the financial statements.

4

REGENERON PHARMACEUTICALS, INC.
CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited)
For the nine months ended September 30, 1998
(In thousands)

Class A Stock		Common Stock		Additional	Unearned
Shares	Amount	Shares	Amount	Paid-in	Compensation
-----	-----	-----	-----	Capital	-----

Balance, December 31, 1997	4,118	\$ 4	26,805	\$ 27	\$ 308,109	(\$720)
Amortization of unearned compensation						270
Issuance of Common Stock in connection with exercise of stock options			92		438	
Conversion of Class A Stock to Common Stock	(486)		486			
Net loss						
Change in net unrealized gain on marketable securities						
Balance, September 30, 1998	3,632	\$ 4	27,383	\$ 27	\$ 308,547	(\$450)

	Accumulated Deficit	Accumulated Other Comprehensive Income	Total Stockholders' Equity	Comprehensive Loss
Balance, December 31, 1997	(\$168,608)	\$ 85	\$138,897	
Amortization of unearned compensation			270	
Issuance of Common Stock in connection with exercise of stock options			438	
Conversion of Class A Stock to Common Stock	(3,084)		(3,084)	(\$3,084)
Net loss				
Change in net unrealized gain on marketable securities		332	332	332
Balance, September 30, 1998	(\$171,692)	\$ 417	\$136,853	(\$2,752)

The accompanying notes are an integral part of the financial statements.

5

REGENERON PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)
Increase (Decrease) in Cash and Cash Equivalents
(In thousands)

	Nine months ended September 30, 1998	1997
Cash flows from operating activities		
Net loss	(\$ 3,084)	(\$12,106)
Adjustments to reconcile net loss to net cash used in operating activities		
Loss in Amgen-Regeneron Partners	1,551	2,834
Depreciation and amortization	2,330	3,336
Stock issued in consideration for services rendered	270	270
Changes in assets and liabilities		
Increase in amounts due from The Procter & Gamble Company	(133)	(958)
(Increase) decrease in amounts due from Merck & Co., Inc.	(365)	313
(Increase) decrease in amounts due from Amgen-Regeneron Partners	(371)	115
Decrease in amounts due from Sumitomo Pharmaceuticals Co., Ltd.	2,049	815
Increase in investment in Amgen-Regeneron Partners	(3,818)	(2,037)
Increase in prepaid expenses and other assets	(702)	(33)
Decrease in deferred revenue	(2,558)	(1,964)
Increase in accounts payable, accrued expenses, and other liabilities	330	190
Total adjustments	(1,417)	2,881
Net cash used in operating activities	(4,501)	(9,225)
Cash flows from investing activities		
Purchases of marketable securities	(74,108)	(72,941)
Sales of marketable securities	75,776	48,941
Capital expenditures	(2,380)	(1,480)
Net cash used in investing activities	(712)	(25,480)
Cash flows from financing activities		
Net proceeds from the issuance of stock	438	43,337

Principal payments on note payable	(57)	(58)
Capital lease payments	(1,495)	(2,761)
	-----	-----
Net cash (used in) provided by financing activities	(1,114)	40,518
	-----	-----
Net (decrease) increase in cash and cash equivalents	(6,327)	5,813
	-----	-----
Cash and cash equivalents at beginning of period	28,921	34,475
	-----	-----
Cash and cash equivalents at end of period	\$22,594	\$40,288
	=====	=====

The accompanying notes are an integral part of the financial statements.

6

REGENERON PHARMACEUTICALS, INC.
Notes to Condensed Financial Statements
(In thousands, except per share data)

1. Interim Financial Statements

The interim Condensed Financial Statements of Regeneron Pharmaceuticals, Inc. (the "Company") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with generally accepted accounting principles. In the opinion of management, these financial statements reflect all adjustments, consisting only of normal recurring accruals, necessary for a fair presentation of the Company's financial position, results of operation, and cash flows for such periods. The results of operations for any interim periods are not necessarily indicative of the results for the full year. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 1997.

2. Statement of Cash Flows

Supplemental disclosure of noncash investing and financing activities:

Capital lease obligations of \$451 and \$812 were incurred during the first nine months of 1998 and 1997, respectively, when the Company leased new equipment.

Included in accounts payable and accrued expenses at September 30, 1998 and December 31, 1997 were approximately \$67 and \$635, respectively, of accrued capital expenditures. Included in accounts payable and accrued expenses at September 30, 1997 and December 31, 1996 were approximately \$417 and \$788, respectively, of accrued capital expenditures.

3. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses as of September 30, 1998 and December 31, 1997 consist of the following:

	September 30, 1998	December 31, 1997
	-----	-----
Accounts payable	\$1,715	\$2,947
Accrued payroll and related costs	1,191	654
Accrued expenses, other	1,202	712
Deferred compensation	287	350
	-----	-----
	\$4,395	\$4,663
	=====	=====

7

REGENERON PHARMACEUTICALS, INC.
Notes to Condensed Financial Statements
(In thousands, except per share data)

4. Amgen-Regeneron Partners Research Collaboration Agreement

In August 1990, the Company and Amgen Inc. formed a partnership, Amgen-Regeneron Partners (the "Partnership"), whereby the revenues earned and expenses incurred by the Partnership for the research and development of BDNF and NT-3 are shared equally. The Company accounts for its investment in the Partnership in accordance with the equity method of accounting.

Selected income statement data of the Partnership for the three and nine months ended September 30, 1998 and 1997 are as follows:

	Three months Ended September 30,		Nine months Ended September 30,	
	1998	1997	1998	1997
Total revenues	\$ 110	\$ 79	\$ 193	\$ 266
Total expenses	(1,465)	(1,388)	(3,294)	(5,934)
Net loss	(\$1,355)	(\$1,309)	(\$3,101)	(\$5,668)

In October 1998, the Company made a capital contribution of \$1,349 to the Partnership.

REGENERON PHARMACEUTICALS, INC.
Notes to Condensed Financial Statements
(In thousands, except per share data)

5. Per Share Data

The Company's basic net loss per share amounts have been computed by dividing net loss by the weighted average number of Common and Class A shares outstanding. For the three months and nine months ended September 30, 1998 and 1997, the Company reported net losses; therefore, no common stock equivalents were included in the computation of diluted net loss per share, since such inclusion would have been antidilutive. The calculations of basic and diluted net loss per share are as follows:

	Three Months Ended September 30,		
	Net Loss (Numerator)	Shares (Denominator)	Per Share Amount
1998:			
Basic and Diluted	(\$1,395)	31,014	(\$ 0.04)
1997:			
Basic and Diluted	(\$1,907)	30,895	(\$ 0.06)

Options and warrants which have been excluded from the diluted per share amounts because their effect would have been anti-dilutive include the following:

	Three Months Ended September 30,			
	1998		1997	
	Weighted	Weighted	Weighted	Weighted

	Average Number	Average Exercise Price	Average Number	Average Exercise Price
	-----	-----	-----	-----
Options and warrants with exercise prices below the average fair market value of the Company's common stock for the respective period	1,898	\$4.70	2,179	\$5.17
Options and warrants with exercise prices above the average fair market value of the Company's common stock for the respective period	4,592	\$11.60	3,652	\$12.31
Total	6,490		5,831	
	=====		=====	

9

REGENERON PHARMACEUTICALS, INC.
Notes to Condensed Financial Statements
(In thousands, except per share data)

5. Per Share Data (continued)

	Nine Months Ended September 30,		
	Net Loss (Numerator)	Shares (Denominator)	Per Share Amount
	-----	-----	-----
1998:			
Basic and Diluted	(\$ 3,084)	30,983	(\$0.10)
1997:			
Basic and Diluted	(\$12,106)	27,962	(\$0.43)

Options and warrants which have been excluded from the diluted per share amounts because their effect would have been anti-dilutive include the following:

	Nine Months Ended September 30,			
	1998		1997	
	Weighted Average Number	Weighted Average Exercise Price	Weighted Average Number	Weighted Average Exercise Price
	-----	-----	-----	-----
Options and warrants with exercise prices below the average fair market value of the Company's common stock for the respective period	1,968	\$4.77	2,192	\$ 5.12
Options and warrants with exercise prices above the average fair market value of the Company's common stock for the respective period	4,458	\$11.71	2,581	\$16.71

Total	----- 6,426 =====	----- 4,773 =====
-------	-------------------------	-------------------------

10

REGENERON PHARMACEUTICALS, INC.
Notes to Condensed Financial Statements
(In thousands, except per share data)

6. Adoption of Statement of Financial Accounting Standards No. 130

The Company has adopted Statement of Financial Accounting Standards No. 130, Reporting Comprehensive Income ("SFAS No. 130"). Comprehensive loss represents the change in net assets of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss of the Company includes net loss adjusted for the change in net unrealized gain or loss on marketable securities. The net effect of income taxes on comprehensive loss is immaterial. The disclosures required by SFAS No. 130 for the nine months ended September 30, 1998 have been included in the Statement of Stockholders' Equity. For the nine months ended September 30, 1998 and 1997, the components of comprehensive loss were:

	1998	1997
Net loss	----- (\$3,084)	----- (\$12,106)
Change in net unrealized gain on marketable securities	332	(193)
Total comprehensive loss	----- (\$2,752) =====	----- (\$12,299) =====

7. Impact of the Future Adoption of Recently Issued Accounting Standard

In June 1998, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 133, Accounting for Derivative and Hedging Activities ("SFAS No. 133"). SFAS No. 133 establishes a comprehensive standard on accounting for derivatives and hedging activities and is effective for periods beginning after June 15, 1999. Management does not believe that the future adoption of SFAS No. 133 will have a material effect on the Company's financial position and results of operations.

11

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

General

Overview. The discussion below contains forward-looking statements that involve risks and uncertainties relating to the future financial performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") and actual events or results may differ materially. These statements concern, among other things, the possible therapeutic applications of the Company's product candidates and research programs, the timing and nature of the Company's clinical and research programs now underway or planned, a variety of items described herein and in the footnotes to the Company's financial statements (including the useful life of assets, the anticipated length of agreements, and other matters), and the future uses of capital and financial needs of the Company. These statements are made by the Company based on management's current beliefs and judgment. In evaluating such statements, stockholders and potential investors should specifically consider the various factors identified under the caption "Factors That May Affect Future Operating Results" which could cause actual results to differ materially from those indicated by such forward-looking statements.

Regeneron is a leader in the application of molecular and cell biology to discover novel potential therapeutics for human medical conditions and is seeking to develop and commercialize these discoveries. The Company is applying its technological expertise in protein growth factors, their receptors, and their mechanisms of action to the discovery and development of protein-based drugs and orally active, small molecule drugs.

The Company is pursuing research and development programs in the following areas:

- o AXOKINE(R), a second generation ciliary neurotrophic factor, for the treatment of obesity associated with Type II diabetes and possibly for uncomplicated obesity,
- o AXOKINE for the treatment of retinitis pigmentosa and other retinal diseases,
- o Brain-derived neurotrophic factor ("BDNF") for the treatment of amyotrophic lateral sclerosis ("ALS," commonly known as Lou Gehrig's disease),
- o Neurotrophin-3 ("NT-3") for the treatment of enteric neuropathies (constipating conditions),
- o Angiopoietins, a new family of ligands (and their receptors, called the TIE family of receptors) that appears to regulate blood vessel formation, or angiogenesis,
- o Protein antagonists for cytokines such as interleukin-4 ("IL-4") and interleukin-6 ("IL-6") as potential treatment of inflammatory diseases, allergic disorders, and cancer,
- o Noggin, a naturally occurring protein, for potential use in treating abnormal bone formation and related diseases and conditions,
- o Muscle atrophy, that occurs in a variety of clinical settings following disuse or denervation of muscle, and

12

- o Research programs to discover orally active, small molecule-based drugs, some of which may mimic or antagonize protein- or receptor-based drug candidates that the Company is developing.

Discussion of Third Quarter 1998 Activities. In the third quarter of 1998, the Company continued to develop AXOKINE under the Company's collaboration agreement ("the P&G Agreement") with The Procter and Gamble Company ("Procter & Gamble"). The Company and Procter & Gamble plan to file an Investigational New Drug application ("IND") with the United States Food and Drug Administration ("FDA") in early 1999 in order to conduct early stage clinical studies of AXOKINE for the treatment of obesity associated with Type II diabetes and possibly for uncomplicated obesity. No assurance can be made regarding the timing or nature of such IND in light of the need successfully to complete substantial preclinical development activities, the timing of which is partially not in the control of the Company or Procter & Gamble, before filing an IND. In addition, no assurance can be made regarding the timing, nature, or result of any clinical trial of AXOKINE. AXOKINE has never been administered to people. Its safety and efficacy in the treatment of any condition have not been established and can not be predicted. Previous clinical studies of ciliary neurotrophic factor ("CNTF"), the parent molecule of AXOKINE, resulted in the creation of antibodies and adverse events (side effects) in patients, including weight loss, cough, nausea, malaise, and others. While certain aspects of the development of AXOKINE by the Company and Procter & Gamble have focused on attempting to avoid or minimize antibody production or adverse events, no assurance may be given that these problems will be avoided or minimized or that they will not lead to the failure, delay, or additional difficulty in conducting AXOKINE clinical trials.

The Company and Procter & Gamble also continued to collaborate in research and development in the fields of angiogenesis, bone growth, and muscle injury and atrophy, as well as small molecule (orally active) drugs. The majority of the Company's scientific resources are devoted to its

collaborative activities with Procter & Gamble.

The Company continued independently to develop AXOKINE for use in treating degenerative retinal diseases. The Company is collaborating with academic investigators, government agencies, and private foundations in the development of AXOKINE for retinal disease. Subject to completion of appropriate preclinical experiments and regulatory approval, the Company plans to commence a Phase I clinical study of AXOKINE to treat retinitis pigmentosa in 1999. In July 1998, the Company and Medtronic, Inc. terminated their 1996 collaborative development agreement to conduct an exploratory research program using Medtronic delivery systems to deliver AXOKINE to the central nervous system, initially as a potential treatment for Huntington's disease, due to obstacles in formulation and delivery.

During the third quarter of 1998, the Company continued to develop independent of any corporate collaboration its proprietary cytokine traps for the potential treatment of inflammatory disease, asthma, cancer, and rheumatoid arthritis. In addition, the Company continued to conduct research with Pharmacocepta, Inc. and Glaxo Wellcome plc in the area of small molecule (orally active) drugs.

During the third quarter of 1998, Amgen-Regeneron Partners, the partnership equally owned by Regeneron and Amgen Inc. ("Amgen"), continued to develop BDNF and NT-3. BDNF is currently being developed by Amgen-Regeneron Partners for potential use in treating ALS through two routes of administration: intrathecal (infusion

13

into the spinal fluid through an implanted pump) and subcutaneous (injection under the skin). Amgen, on behalf of Amgen-Regeneron Partners, has completed a Phase I safety study and started a Phase II clinical trial of BDNF delivered intrathecally. Subcutaneous studies conducted by Regeneron on behalf of the partnership began in the first quarter of 1998. The subcutaneous studies are based on an analysis of the Amgen-Regeneron Partners Phase III trial of BDNF for ALS that was completed in 1996. That trial failed to achieve its predetermined end points, but subsequent analyses indicated that a retrospectively-defined subset of ALS patients in the trial may have received a survival benefit from BDNF treatment.

The Company and Sumitomo Pharmaceuticals Co., Ltd. ("Sumitomo Pharmaceuticals") are collaborating in the development of BDNF in Japan, initially for the treatment of ALS. In March 1998, Sumitomo Pharmaceuticals initiated a Phase I clinical trial in Japan to assess the safety of BDNF delivered subcutaneously to normal volunteers. In August 1998, Sumitomo Pharmaceuticals signed a license agreement for the development of BDNF in Japan. Pursuant to the license agreement, Sumitomo Pharmaceuticals made a \$5.0 million research progress payment to Regeneron in August 1998 and will make additional payments upon the achievement of specified milestones. Sumitomo Pharmaceuticals will also pay a royalty on sales of BDNF in Japan.

Amgen-Regeneron Partners' clinical development of NT-3 is currently focused on enteric neuropathies (constipating conditions). The enteric nervous system is a complex collection of nerves that control the function of the gastrointestinal system, including gastrointestinal motility. In June 1998, Regeneron, on behalf of Amgen-Regeneron Partners, began the first of a series of small clinical studies of NT-3 in enteric neuropathies. The initial study included patients suffering from severe idiopathic constipation. Additional studies have begun in patients who suffer from constipation associated with Parkinson's disease and use of opiate pain-killers.

No assurance can be given that extended administration of BDNF or NT-3 will be safe or effective. The treatment of ALS has been shown, in a number of clinical settings using a variety of treatment modalities (including Amgen-Regeneron Partners' earlier clinical studies), to present significant difficulties. The design of an ALS clinical study presents special difficulties and risks, as do the facts that ALS is a progressive disease that afflicts individual patients differently and other ALS treatments are approved or have been or are currently being tested, creating the possibility that patients in any BDNF study may also receive other therapeutics during all or part of the BDNF trial. The treatment of various constipating conditions may present additional clinical trial risks in light of the complex and not wholly understood mechanisms of action that lead to the conditions, the concurrent

use of other drugs to treat the underlying illnesses as well as the gastrointestinal condition, the potential difficulty of designing and achieving significant clinical end points, and other factors. No assurance can be given that these or any other studies of BDNF or NT-3 will be successful or that BDNF or NT-3 will be commercialized.

Substantial risk is inherent in the research, development, and commercialization of drugs. In addition, in each of the areas of the Company's independent and collaborative activities, other companies and entities are actively pursuing competitive paths toward similar objectives. The results of the Company's and its collaborators' past activities in connection with the research and development of AXOKINE, cytokine traps, angiopoietins, abnormal bone growth, muscle atrophy, small molecules, BDNF, and NT-3 do not necessarily predict the results or success of current or future activities including, but not limited to, any additional preclinical or clinical studies. The Company cannot

14

predict whether, when, or under what conditions any of its research or product candidates, including without limitation AXOKINE, BDNF, or NT-3, will be shown to be safe or effective to treat any human condition or be approved for marketing by any regulatory agency. The delay or failure of current or future studies to demonstrate the safety or efficacy of the Company's product candidates to treat human conditions or to be approved for marketing could have a material adverse impact on the Company.

To date, Regeneron has not received any revenues from the commercial sale of products and may never receive such revenues. Before such revenues can be realized, the Company (or its collaborators) must overcome a number of hurdles which include successfully completing its research and development efforts and obtaining regulatory approval from the FDA or regulatory authorities in other countries. In addition, the biotechnology and pharmaceutical industries are rapidly evolving and highly competitive, and new developments may render the Company's products and technologies noncompetitive and obsolete.

From inception on January 8, 1988 through September 30, 1998, Regeneron had a cumulative loss of \$171.7 million. In the absence of revenues from commercial product sales or other sources (the amount, timing, nature, or source of which cannot be predicted), the Company's losses will continue as the Company conducts its research and development activities. The Company's activities may expand over time and may require additional resources, and the Company's operating losses may be substantial over at least the next several years. The Company's losses may fluctuate from quarter to quarter and will depend, among other factors, on the timing of certain expenses and on the progress of the Company's research and development efforts.

Results of Operations

Three months ended September 30, 1998 and 1997. The Company's total revenue increased to \$12.6 million for the third quarter of 1998 from \$8.9 million for the same period in 1997. Contract research and development revenue increased to \$4.0 million for the third quarter of 1998 from \$3.3 million for the same period in 1997, as higher revenue related to the P&G Agreement more than offset a decrease in revenue from Sumitomo Pharmaceuticals. In the third quarter of 1998, a research progress payment of \$5.0 million (reduced by \$0.5 million of Japanese withholding tax) was received from Sumitomo Pharmaceuticals related to the development of the Company's BDNF in Japan. A research progress payment of \$2.5 million was received from Procter & Gamble in the third quarter of 1997 related to the P&G Agreement. Contract manufacturing revenue related to the long-term manufacturing agreement (the "Merck Agreement") with Merck & Co., Inc. ("Merck") increased to \$2.3 million for the third quarter of 1998 compared to \$1.3 million for the same period in 1997 as a result of increased activity in preparation for manufacturing a product for Merck at the Company's Rensselaer facility.

The Company's total operating expenses increased to \$14.0 million in the third quarter of 1998 from \$10.8 million for the same period in 1997. Research and development expenses increased to \$9.9 million in the third quarter of 1998 from \$6.8 million for the same period in 1997, primarily as a result of additional employees and increased activity in the Company's preclinical and clinical research programs. Research and development expenses

(including loss in Amgen-Regeneron Partners) were approximately 76% of total operating expenses in the third quarter of 1998, compared to 69% for the same period in 1997.

15

General and administrative expenses decreased to \$1.3 million in the third quarter of 1998 from \$1.4 million for the same period of 1997. Depreciation and amortization expense decreased to \$0.7 million in the third quarter of 1998 from \$1.0 million in the third quarter of 1997, as certain laboratory equipment and leasehold improvements became fully depreciated. Contract manufacturing expenses, which are expenses directly related to the Merck Agreement and are reimbursed by Merck, increased to \$1.3 million in the third quarter of 1998 from \$0.8 million in the same period of 1997, primarily due to increased activity in preparation for manufacturing a product for Merck.

The Company's net loss for the third quarter of 1998 was \$1.4 million, or \$0.04 per share (basic and diluted), compared to a net loss of \$1.9 million, or \$0.06 per share (basic and diluted), for the same period in 1997.

Nine months ended September 30, 1998 and 1997. The Company's total revenue increased to \$36.0 million for the nine months ended September 30, 1998 from \$21.7 million for the same period in 1997. Contract research and development revenue increased to \$14.8 million for the nine months ended September 30, 1998 from \$11.9 million for the same period in 1997, as higher revenue related to the P&G Agreement more than offset a decrease in revenue from Sumitomo Pharmaceuticals. In 1998, research progress payments of \$9.5 million consist of a payment of \$5.0 million from Sumitomo Pharmaceuticals related to the development of the Company's BDNF in Japan (reduced by \$0.5 million of Japanese withholding tax) and a payment of \$5.0 million from Procter & Gamble in connection with a collaboration to develop AXOKINE for obesity associated with Type II diabetes and possibly for uncomplicated obesity. In the first nine months of 1997 a research progress payment of \$2.5 million was received from Procter & Gamble in connection with the P&G Agreement. Contract manufacturing revenue related to the Merck Agreement increased to \$6.5 million for the first nine months of 1998 compared to \$2.9 million for the same period in 1997 as a result of increased activity in preparation for manufacturing a product for Merck at the Company's Rensselaer facility. Investment income for the nine months ended September 30, 1998 increased to \$5.3 million from \$4.5 million for the same period in 1997, due mainly to higher levels of interest-bearing investments resulting primarily from the proceeds of a private placement of equity securities with Procter & Gamble in June 1997.

The Company's total operating expenses increased to \$39.1 million for the nine months ended September 30, 1998 from \$33.8 million for the same period in 1997. Research and development expenses increased to \$27.1 million in the first nine months of 1998 from \$20.8 million for the same period in 1997, primarily as a result of additional employees and increased activity in the Company's preclinical and clinical research programs. Loss in Amgen-Regeneron Partners decreased to \$1.6 million in the first nine months of 1998 from \$2.8 million for the same period in 1997, due to lower research and development expenses by the Partnership. Research and development expenses (including loss in Amgen-Regeneron Partners) were approximately 73% of total operating expenses in the first nine months of 1998, compared to 70% for the same period in 1997.

General and administrative expenses decreased to \$4.4 million for the nine months ended September 30, 1998 from \$4.6 million for the same period in 1997. Depreciation and amortization expense decreased to \$2.3 million for the nine months ended September 30, 1998 from \$3.3 million for the same period in 1997, as certain laboratory equipment and leasehold improvements became fully depreciated. Contract manufacturing expenses, which are expenses directly related to the Merck Agreement and are reimbursed by Merck, increased to \$3.4 million in the first nine months of 1998 from

16

\$1.7 million in the same period of 1997, primarily due to increased activity

in preparation for manufacturing a product for Merck. Interest expense decreased to \$0.3 million from \$0.6 million for the nine months ended September 30, 1998 and 1997, respectively, as the amount of outstanding obligations in connection with capital leases declined.

The Company's net loss for the nine months ended September 30, 1998 was \$3.1 million, or \$0.10 per share (basic and diluted), compared to a net loss of \$12.1 million, or \$0.43 per share (basic and diluted), for the same period in 1997.

Liquidity and Capital Resources

Since its inception in 1988, the Company has financed its operations primarily through private placements and public offerings of its equity securities, revenue earned under the several agreements between the Company and each of Amgen, Sumitomo Chemical Company, Ltd., Sumitomo Pharmaceuticals, Merck, and Procter & Gamble and investment income.

In May 1997, the Company and Procter & Gamble entered into the P&G Agreement. Procter & Gamble agreed over the first five years of the P&G Agreement to purchase up to \$60.0 million in Regeneron equity (of which \$42.9 million was purchased in June 1997) and provide up to \$94.7 million in support of Regeneron's research efforts related to the collaboration. During the second five years of the P&G Agreement, the companies will share all research costs equally. Clinical testing and commercialization expenses for jointly developed products will be shared equally throughout the ten years of the collaboration. The companies expect jointly to develop and market worldwide any products resulting from the collaboration and share equally in profits. Either company may terminate the P&G Agreement at the end of five years with at least one year prior notice or earlier in the event of a default (as defined in the P&G Agreement). In September 1997, the Company and Procter & Gamble expanded the P&G Agreement to include AXOKINE and related molecules (delivered systemically), and agreed to develop AXOKINE initially to treat obesity associated with Type II diabetes. Procter & Gamble agreed to reimburse the Company for certain research and development costs and pay as much as \$15.0 million in additional funding, partly subject to achieving certain milestones related to AXOKINE. Of the \$15.0 million, \$5.0 million was paid in 1997 and \$5.0 million was paid in 1998.

In connection with the Company's agreement to collaborate with Sumitomo Pharmaceuticals in the research and development of BDNF in Japan, the Company continues to be reimbursed in connection with supplying Sumitomo Pharmaceuticals with BDNF for preclinical and clinical use. The Company also received a \$5.0 million research progress payment from Sumitomo Pharmaceuticals (reduced by \$0.5 million of Japanese withholding tax) in August 1998.

The Company's activities relating to BDNF and NT-3, as agreed upon by Amgen and Regeneron, are being reimbursed by Amgen-Regeneron Partners, and the Company recognizes such reimbursement as revenue. The funding of Amgen-Regeneron Partners is through capital contributions from Amgen and Regeneron, who must make equal payments in order to maintain equal ownership and equal sharing of any profits or losses from the partnership. The Company has made capital contributions totaling approximately \$49.0 million to Amgen-Regeneron Partners from the partnership's inception in June 1993 through September 30, 1998. The Company expects that its capital contributions in 1998 will total \$5.2 million for the full year, all of which has been

funded through October 1998. These contributions could increase or decrease, depending upon the cost of Amgen-Regeneron Partners' conducting additional BDNF and NT-3 studies and the outcomes of those and other ongoing studies.

From its inception in January 1988 through September 30, 1998, the Company invested approximately \$58.6 million in property, plant, and equipment. This includes \$16.8 million to acquire and renovate the Rensselaer facility and an additional \$14.1 million to complete construction at the facility pursuant to the Merck Agreement. In connection with the purchase and renovation of the Rensselaer facility, the Company obtained financing of \$2.0 million from the New York State Urban Development Corporation, of which \$1.7 million is outstanding. Under the terms of such financing, the Company is not

permitted to declare or pay dividends on its equity securities.

The Company expects that expenses related to the filing, prosecution, defense, and enforcement of patent and other intellectual property claims will continue to be substantial as a result of patent filings and prosecutions in the United States and foreign countries. The Company is currently involved in interference proceedings in the Patent and Trademark Office between Regeneron's patent applications and patents relating to CNTF issued to Synergen, Inc. ("Synergen"). Amgen acquired all outstanding shares of Synergen in 1994. In March 1998, the Company and Amgen entered into a covenant not to sue each other which, among other things, resolved their patent interference and related patent proceedings relating to CNTF and AXOKINE. The Company also granted Amgen a license to use CNTF and second generation CNTFs other than AXOKINE to treat retinal degenerative conditions. Neither party will pay royalties or make other payments to the other party in consideration of this agreement.

As of September 30, 1998, the Company had no established banking arrangements through which it could obtain short-term financing or a line of credit. Additional funds may be raised through, among other things, the issuance of additional securities, other financing arrangements, and future collaboration agreements. No assurance can be given that additional financing will be available or, if available, that it will be available on acceptable terms. In addition, the Company estimates that through mid-2002 it could receive additional payments from Procter & Gamble in the form of research funding, milestones, and equity purchases of as much as \$100 million or more.

At September 30, 1998, the Company had \$120.4 million in cash, cash equivalents, and marketable securities. The Company expects to incur substantial funding requirements for, among other things, research and development activities (including preclinical and clinical testing), validation of manufacturing facilities, and the acquisition of equipment. The Company expects to incur ongoing funding requirements for capital contributions to Amgen-Regeneron Partners to support the continued development and clinical trials of BDNF and NT-3. The amount needed to fund operations will also depend on other factors, including the status of competitive products, the success of the Company's research and development programs, the status of patents and other intellectual property rights developments, and the continuation, extent, and success of any collaborative research programs (including those with Amgen and Procter & Gamble). The Company believes that its existing capital resources will enable it to meet operating needs for at least several years. No assurance can be given that there will be no change in projected revenues or expenses that would lead to the Company's capital being consumed significantly before such time.

Factors That May Affect Future Operating Results

Regeneron cautions stockholders and potential investors that the following important factors, among others, in some cases have affected, and in the future could affect, Regeneron's actual results and could cause Regeneron's actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, Regeneron. The statements under this caption are intended to serve as cautionary statements within the meaning of the Private Securities Litigation Reform Act of 1995. The following information is not intended to limit in any way the characterization of other statements or information under other captions as cautionary statements for such purpose:

- o Delay, difficulty, or failure of the Company's research and development programs to produce product candidates that are scientifically or commercially appropriate for further development by the Company or others.
- o Cancellation or termination of material collaborative or licensing agreements (including in particular, but not limited to, those with Procter & Gamble and Amgen) and the resulting loss of research or other funding could have a material adverse effect on the Company and its operations. A change of control of one or more of the Company's material collaborators or licensees could also have a material adverse effect on the Company.

- o Delay, difficulty, or failure of a clinical trial of any of the Company's product candidates. A clinical trial can fail or be delayed as a result of many causes, including, among others, failure of the product candidate to demonstrate safety or efficacy, the development of serious or life-threatening adverse events (side effects) caused by or connected with exposure to the product candidate, the creation of antibodies (in the case of protein-based therapeutics) that weaken or neutralize the effect of the product candidate (and possibly could have other adverse effects on patients), the failure of clinical investigators, trial monitors and other consultants, or trial subjects to comply with the trial plan or protocol.
- o Delay, difficulty, or failure in obtaining regulatory approval (including approval of its facilities for production) for the Company's products (including vaccine intermediate for Merck), including delays or difficulties in development because of insufficient proof of safety or efficacy.
- o Increased and irregular costs of development, manufacture, regulatory approval, sales, and marketing associated with the introduction of products in the late stage of development.
- o Competitive or market factors that may cause use of the Company's products to be limited or otherwise fail to achieve broad acceptance.
- o The ability to obtain, maintain, and prosecute intellectual property rights, and the cost of acquiring in-process technology and other intellectual property rights, either by license, collaboration, or purchase of another entity.

19

- o Difficulties or high costs of obtaining adequate financing to meet the Company's obligations under its collaboration and licensing agreements or to fund 50 percent of the cost of developing product candidates in order to retain 50 percent of the commercialization rights.
- o Amount and rate of growth of Regeneron's general and administrative expenses, and the impact of unusual charges resulting from Regeneron's ongoing evaluation of its business strategies and organizational structure.
- o Failure of corporate partners to develop or commercialize successfully the Company's products or to retain and expand the markets served by the commercial collaborations; conflicts of interest, priorities, and commercial strategies which may arise between the Company and such corporate partners.
- o Delays or difficulties in developing and acquiring production technology and technical and managerial personnel to manufacture novel biotechnology products in commercial quantities at reasonable costs and in compliance with applicable quality assurance and environmental regulations and governmental permitting requirements.
- o Difficulties in obtaining key raw materials and supplies for the manufacture of the Company's product candidates.
- o The costs and other effects of legal and administrative cases and proceedings (whether civil, such as product- or employment-related, or environmental, or criminal); settlements and investigations; developments or assertions by or against Regeneron relating to intellectual property rights and licenses; the issuance and use of patents and proprietary technology by Regeneron and its competitors, including the possible negative effect on the Company's ability to develop, manufacture, and sell its products in circumstances where it is unable to obtain licenses to patents which may be required for such products.
- o Underutilization of the Company's existing or new manufacturing

facilities or of any facility expansions, resulting in inefficiencies and higher costs; start-up costs, inefficiencies, delays, and increased depreciation costs in connection with the start of production in new plants and expansions.

- o Health care reform, including reductions or changes in reimbursement available for prescription medications or other reforms.
- o The ability to attract and retain key personnel. As Regeneron's scientific efforts lead to potentially promising new directions, both outside of recombinant protein therapies (into orally active, small molecule pharmaceuticals) and outside of treatments for neurological and neurodegenerative conditions (into, for example, potential programs in obesity, diabetes, cancer, inflammation, muscle disease, bone growth disorders, and angiogenesis), the Company will require additional internal expertise or external collaborations in areas in which it currently does not have substantial resources and personnel.

20

1

The Company is evaluating its operations to determine the impact, if any, Year 2000 issues may have. The Company's review includes its computer systems and software, embedded systems in non-computer equipment, and vendor operations. The Company has appointed a Year 2000 task force with representatives from each operation of the Company and has retained independent consultants to facilitate its review. To date, the Company believes that no material Year 2000 issue exists with respect to its computer systems and software. The Company is in the process of analyzing its laboratory and manufacturing equipment with embedded systems. This analysis is incomplete. The Company is also in the process of surveying its vendors to determine their level of readiness with respect to Year 2000 issues. The analysis of the Company's embedded systems and the information collected regarding vendor readiness will be used to formulate a contingency plan with respect to reasonably identifiable items of equipment and supply of materials that are critical to the Company's operations. The costs of addressing Year 2000 issues have been minor to date, but may increase if substantial consultant or personnel resources are required or if operationally-important equipment must be remediated or replaced. Because the Company's analysis of Year 2000 issues is incomplete, at this time management cannot estimate the total expected costs of Year 2000 issues. The risks that Year 2000 issues could present to the Company include, without limitation, disruption, delay, or cessation of manufacturing or other operations, including operations that are subject to regulatory compliance. In each case the correction of the problem could result in substantial expense and disruption or delay of the Company's operations.

Impact of the Future Adoption of Recently Issued Accounting Standard

In June 1998, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 133, Accounting for Derivative and Hedging Activities ("SFAS No. 133"). SFAS No. 133 establishes a comprehensive standard on accounting for derivatives and hedging activities and is effective for periods beginning after June 15, 1999. Management does not believe that the future adoption of SFAS No. 133 will have a material effect on the Company's financial position and results of operations.

21

PART II. OTHER INFORMATION

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

- (a) Exhibits

(b) Reports

No reports on Form 8-K were filed by the Registrant during the quarter ended September 30, 1998.

22

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Regeneron Pharmaceuticals, Inc.

Date: November 5, 1998

By: /s/ Murray A. Goldberg

Murray A. Goldberg
Vice President, Finance & Administration,
Chief Financial Officer, and Treasurer

23

<ARTICLE> 5
<MULTIPLIER> 1000

<PERIOD-TYPE>	9-MOS
<FISCAL-YEAR-END>	DEC-31-1998
<PERIOD-START>	JAN-01-1998
<PERIOD-END>	SEP-30-1998
<CASH>	22,594
<SECURITIES>	97,784
<RECEIVABLES>	5,401
<ALLOWANCES>	0
<INVENTORY>	0
<CURRENT-ASSETS>	89,217
<PP&E>	58,571
<DEPRECIATION>	25,925
<TOTAL-ASSETS>	162,439
<CURRENT-LIABILITIES>	9,628
<BONDS>	0
<PREFERRED-MANDATORY>	0
<PREFERRED>	0
<COMMON>	31
<OTHER-SE>	136,822
<TOTAL-LIABILITY-AND-EQUITY>	162,439
<SALES>	0
<TOTAL-REVENUES>	36,011
<CGS>	0
<TOTAL-COSTS>	0
<OTHER-EXPENSES>	38,765
<LOSS-PROVISION>	0
<INTEREST-EXPENSE>	330
<INCOME-PRETAX>	(3,084)
<INCOME-TAX>	0
<INCOME-CONTINUING>	(3,084)
<DISCONTINUED>	0
<EXTRAORDINARY>	0
<CHANGES>	0
<NET-INCOME>	(3,084)
<EPS-PRIMARY>	(0.10)
<EPS-DILUTED>	(0.10)